Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 8, 2009

BioFocus Gains Access to DiscoveRx GPCR and cAMP Assays

  • BioFocus and DiscoveRx signed a co-marketing agreement that will allow BioFocus to carry out screening for clients using DiscoveRx' PathHunter™ ß-Arresting GPCR screening assay, HitHunter™ cAMP assays, and associated cell lines.

    The deal with BioFocus comes just days after DiscoveRx signed a global agreement with GlaxoSmithKline to provide the latter with access to its PathHunter™ ß-Arrestin parental cell lines, clones, and associated reagents for use in GSK's GPCR screening and profiling research. This agreement followed closely behind DiscoveRx and GSK's announcement of a three-way alliance with Medical Research Council Technology, focused on using the PathHunter™ ß-Arrestin assay technology to find binders to orphan GPCRs.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »